Short description
NovaBiotics Ltd is a clinical-stage biotechnology company.
Description
NovaBiotics Ltd is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.
The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®).
NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals.
Total funding
$$2020202
Sign in for full access
Location
Aberdeen, Aberdeen City, United Kingdom, Europe
Founded on
January 1, 2004
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$1230 - 4560
Sign in for full access
Investors
Noaccess, Nopepepe, Noaccess, No Way
Sign in for full access
Founders
Deborah O'Neil